CCMI

CCMI is a positive allosteric modulator (PAM) of alpha7 nicotinic acetylcholine receptors (nAChRs). It enhances ACh-, nicotine-, or choline-induced currents in Xenopus oocytes expressing recombinant human alpha7 nAChRs (EC50s = 0.7, 0.6, and 0.5 µM, respectively). In vivo, CCMI (0.3 and 1 mg/kg, i.v.) improves sensory gating deficits in a paired auditory stimulus paradigm in mice. It decreases the latency to find the platform in the Morris water maze test in a rat model of traumatic brain injury (TBI) induced by parasagittal fluid-percussion.Formal Name: N-(4-chlorophenyl)-alpha-[[(4-chlorophenyl)amino]methylene]-3-methyl-5-isoxazoleacetamide. CAS Number: 917837-54-8. Synonyms: AVL-3288, XY-4083. Molecular Formula: C19H15Cl2N3O2. Formula Weight: 388.3. Purity: >95%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Soluble. SMILES: O=C(C(C1=CC(C)=NO1)=CNC2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)Cl. InChi Code: InChI=1S/C19H15Cl2N3O2/c1-12-10-18(26-24-12)17(11-22-15-6-2-13(20)3-7-15)19(25)23-16-8-4-14(21)5-9-16/h2-11,22H,1H3,(H,23,25). InChi Key: VMAKIACTLSBBIY-UHFFFAOYSA-N.